Therapy-induced senescent-like cancer cells drive macrophage-mediated immunosuppression in cholangiocarcinoma
Binbin LiiD, Jingchun YangiD, Meina CaiiD, Shelby K. Yee, Danielle Marie CarlsoniD, Rory L. SmootiD, Darren J. BakeriD, Sumera Irie IlyasiD
Abstract
Cholangiocarcinoma (CCA) is a lethal biliary cancer in which chemoresistance is nearly universal, and its tumor immune microenvironment is dominated by immunosuppressive tumor-associated macrophages (TAMs) that exclude cytotoxic CD8+ T cells. How tumor cells sustain this immunosuppressive state during chemotherapy is undefined. Here we demonstrate that therapy-induced senescent-like (Sen-L) cancer cells accumulate after gemcitabine/cisplatin in human and murine CCA, are predominantly cancer cells, and predict shorter survival. Genetic elimination of Sen-L cancer cells reduces tumor burden, lowers TAM abundance, and restores intratumoral CD8+ T cells, establishing them as causal drivers. Growth differentiation factor 15 (GDF-15) is the dominant Sen-L-secreted factor and reprograms macrophages to suppress CD8+ T cells through the non-canonical receptor TGFBR2 and STAT6, and p16-restricted Gdf15 silencing phenocopies Sen-L elimination. Combined with chemotherapy, Sen-L elimination improves survival beyond chemotherapy alone. These findings establish Sen-L cancer cells and their GDF-15 output as causal, targetable drivers of macrophage-mediated immune evasion in CCA. SIGNIFICANCE STATEMENTTherapy-induced senescent-like cancer cells, not stromal cells, are the dominant senescent-like and immunosuppressive population in cholangiocarcinoma, and their elimination restores antitumor immunity. GDF-15 is their dominant secreted effector and engages a non-canonical macrophage receptor, TGFBR2, identifying a cancer-cell-to-macrophage axis and a Sen-L-elimination strategy to restore chemosensitivity. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=170 SRC="FIGDIR/small/734341v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@7d3fd8org.highwire.dtl.DTLVardef@ea9efborg.highwire.dtl.DTLVardef@16ba16borg.highwire.dtl.DTLVardef@132b821_HPS_FORMAT_FIGEXP M_FIG Graphical abstract. Senescent-like CCA cells promote tumor immunosuppression through TAMs polarization by GDF-15 C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multimodal single-cell profiling reveals cancer crosstalk between macrophages and stromal cells in poor prognostic cholangiocarcinoma patients.
Lara Rosaline Heij, Sikander Hayat, … Ulf P. Neumann·npj Precision OncologyPeer-reviewed·Jan 28, 2026
- The efficacy of chemotherapy is limited by intratumoural senescent cells that persist through the upregulation of PD-L2
S. Chaib, J. A. Lopez-Dominguez, … M. Serrano·bioRxiv·Nov 4, 2022
- Induction of senescence renders cancer cells highly immunogenic
I. Marin, O. Boix, … M. Serrano·bioRxiv·Jun 5, 2022
- CEACAM5/6+ Tumor Cells and IL-1β+ Macrophages Drive Resistance to Chemo-immunotherapy in Gastric Cancer
Jian Chen, Liudeng Zhang, … Han Liang·bioRxiv·Mar 8, 2026
- KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regression
Youwei Qiao, Matthew F. Yee, … Wen Xue·Advanced SciencePeer-reviewed·Dec 3, 2025
- TIGIT drives the immunosuppressive environment by downregulation of metalloproteinases MMP2 and MMP14 in perihilar cholangiocarcinoma.
L. Heij, K. Reichel, … U. Neumann·bioRxiv·Aug 14, 2023